ClinicalTrials.gg
CompletedNCT03143153CheckMate 648Updated Feb 17, 2026Results posted

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

A Phase 3 interventional study of Nivolumab and Ipilimumab in Various Advanced Cancer, sponsored by Bristol-Myers Squibb. Completed at 190 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
970
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin

02

Conditions studied

  • Various Advanced Cancer
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have confirmed squamous cell carcinoma or adenosquamous cell carcinoma of esophagus
  • Male or Female at least 18 years of age
  • Must have esophageal cancer that cannot be operated on, or treated with definitive chemoradiation with curative intent, that is advanced, reoccurring or has spread out
  • Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work
  • Must agree to provide tumor tissue sample, either from a previous surgery or within 6 months or fresh, prior to the start of treatment in this study

Exclusion criteria

Exclusion Criteria

  • Presence of tumor cells in the brain or spinal cord which are symptomatic or require treatment
  • Active known or suspected disease
  • Any serious or uncontrolled medical disorder or active infection
  • Known history of positive test for (HIV) or known acquired immunodeficiency syndrome (AIDS)
  • Any positive test result for or C indicating acute or chronic infection and/or detectable virus

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
970 participants (actual)

Study arms

  • Experimental
    Nivolumab + Ipilimumab

    Biological: Nivolumab · Biological: Ipilimumab

  • Experimental
    Nivolumab + Cisplatin + Fluorouacil

    Biological: Nivolumab · Drug: Cisplatin · Drug: Fluorouracil

  • Active comparator
    Cisplatin + Fluorouracil

    Drug: Cisplatin · Drug: Fluorouracil

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: BMS-936558 (Nivolumab), Opdivo (Nivolumab)

  • BiologicalIpilimumab

    Specified dose on specified days

    Also known as: BMS-734016 (Ipilimumab), Yervoy (Ipilimumab)

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in Participants With Tumor Cell PD-L1

    Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the subject was known to be alive.

    Time frame: From the date of randomization to up to the date of death (up to approximately 20 months)

  2. Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1

    Progression-free survival (PFS) is defined as the time from randomization to the date of the first documented progressive disease (PD) per Blinded Independent Central Review (BICR) or death due to any cause. Participants who die without a reported prior PD per BICR (and die without start of subsequent therapy) will be considered to have progressed on the date of death. Participants who did not have documented PD per BICR per RECIST1.1 criteria and who did not die, will be censored at the date of the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on-study tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date. Participants who started any subsequent anti-cancer therapy without a prior reported PD per BICR will be censored at the last tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.

    Time frame: From the date of randomization to up to the date of the first documented disease progression or death (up to approximately 9 months)

Secondary outcomes

  1. Overall Survival (OS) in All Randomized Participants

    Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the subject was known to be alive.

    Time frame: From the date of randomization to up to the date of death (up to approximately 88 months)

  2. Progression-free Survival (PFS) in All Randomized Participants as Assessed by BICR

    Progression-free survival (PFS) is defined as the time from randomization to the date of the first documented progressive disease (PD) per Blinded Independent Central Review (BICR) or death due to any cause. Participants who die without a reported prior PD per BICR (and die without start of subsequent therapy) will be considered to have progressed on the date of death. Participants who did not have documented PD per BICR per RECIST1.1 criteria and who did not die, will be censored at the date of the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on-study tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date. Participants who started any subsequent anti-cancer therapy without a prior reported PD per BICR will be censored at the last tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.

    Time frame: From the date of randomization to up to the date of the first documented disease progression or death (up to approximately 88 months)

  3. Objective Response Rate (ORR) as Assessed by BICR

    Objective response rate (ORR) is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). Best overall response (BOR) is defined as the best response designation as determined by BICR, recorded between the date of randomization and the date of objectively documented progression (per RECIST 1.1) or the date of subsequent anti-cancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions. Complete response is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.

    Time frame: From the date of randomization to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 88 months)

07

Results

Posted Mar 2, 2022

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestoneArm A: Nivolumab + IpilimumabArm B: Nivolumab + ChemotherapyArm C: Chemotherapy
Started325321324
Completed322310304
Not completed31120
Withdrew: Participant request to discontinue study treatment002
Withdrew: Participant withdrew consent0112
Withdrew: Participant no longer meets study criteria042
Withdrew: Other reasons121
Withdrew: Disease progression112
Withdrew: Adverse event unrelated to study drug131
Treatment
Participant flow — Treatment
MilestoneArm A: Nivolumab + IpilimumabArm B: Nivolumab + ChemotherapyArm C: Chemotherapy
Started322310304
Completed000
Not completed322310304
Withdrew: Disease progression182191199
Withdrew: Study drug toxicity593638
Withdrew: Death644
Withdrew: Adverse event unrelated to study drug192611
Withdrew: Participant request to discontinue study treatment132221
Withdrew: Participant withdrew consent3412
Withdrew: Pregnancy100
Withdrew: Maximum clinical benefit134
Withdrew: Completed treatment as per protocol28140
Withdrew: Other reasons101015

Outcome measures

PrimaryOverall Survival (OS) in Participants With Tumor Cell PD-L1

Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the subject was known to be alive.

Time frame:
From the date of randomization to up to the date of death (up to approximately 20 months)
Reported as:
Median · Months
Overall Survival (OS) in Participants With Tumor Cell PD-L1
MonthsArm A: Nivolumab + IpilimumabArm B: Nivolumab + ChemotherapyArm C: Chemotherapy
Overall Survival (OS) in Participants With Tumor Cell PD-L113.70 (11.24 to 17.02)15.44 (11.93 to 19.52)9.07 (7.69 to 9.95)
Statistical analysis
  • Arm A: Nivolumab + Ipilimumab vs Arm C: Chemotherapy · Log Rank · p = 0.0010 (Log-rank test stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (\<= 1 vs. \>= 2) as recorded in IRT.) · Hazard ratio (hr): 0.64 · 98.6% CI 0.46 to 0.90Stratified Cox proportional hazard model.
  • Arm A: Nivolumab + Ipilimumab vs Arm C: Chemotherapy · Log Rank · p = 0.0010 (Log-rank test stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (\<= 1 vs. \>= 2) as recorded in IRT.) · Hazard ratio (hr): 0.64 · 95% CI 0.49 to 0.84Stratified Cox proportional hazard model
  • Arm B: Nivolumab + Chemotherapy vs Arm C: Chemotherapy · Log Rank · p = <0.0001 (Log-rank test stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (\<= 1 vs. \>= 2) as recorded in IRT.) · Hazard ratio (hr): 0.54 · 99.5% CI 0.37 to 0.80Stratified Cox proportional hazard model
  • Arm B: Nivolumab + Chemotherapy vs Arm C: Chemotherapy · Log Rank · p = <0.0001 (Log-rank test stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (\<= 1 vs. \>= 2) as recorded in IRT.) · Hazard ratio (hr): 0.54 · 95% CI 0.41 to 0.71Stratified Cox proportional hazard model
PrimaryProgression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1

Progression-free survival (PFS) is defined as the time from randomization to the date of the first documented progressive disease (PD) per Blinded Independent Central Review (BICR) or death due to any cause. Participants who die without a reported prior PD per BICR (and die without start of subsequent therapy) will be considered to have progressed on the date of death. Participants who did not have documented PD per BICR per RECIST1.1 criteria and who did not die, will be censored at the date of the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on-study tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date. Participants who started any subsequent anti-cancer therapy without a prior reported PD per BICR will be censored at the last tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.

Time frame:
From the date of randomization to up to the date of the first documented disease progression or death (up to approximately 9 months)
Reported as:
Median · Months
Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1
MonthsArm A: Nivolumab + IpilimumabArm B: Nivolumab + ChemotherapyArm C: Chemotherapy
Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L14.04 (2.40 to 4.93)6.93 (5.68 to 8.34)4.44 (2.89 to 5.82)
Statistical analysis
  • Arm A: Nivolumab + Ipilimumab vs Arm C: Chemotherapy · Log Rank · p = 0.8958 (Log-rank test stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (\<= 1 vs. \>= 2) as recorded in IRT) · Hazard ratio (hr): 1.02 · 98.5% CI 0.73 to 1.43Stratified Cox proportional hazard model
  • Arm A: Nivolumab + Ipilimumab vs Arm C: Chemotherapy · Log Rank · p = 0.8958 (Log-rank test stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (\<= 1 vs. \>= 2) as recorded in IRT) · Hazard ratio (hr): 1.02 · 95% CI 0.78 to 1.34Stratified Cox proportional hazard model
  • Arm B: Nivolumab + Chemotherapy vs Arm C: Chemotherapy · Log Rank · p = 0.0023 (Log-rank test stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (\<= 1 vs. \>= 2) as recorded in IRT) · Hazard ratio (hr): 0.65 · 98.5% CI 0.46 to 0.92Stratified Cox proportional hazard model
  • Arm B: Nivolumab + Chemotherapy vs Arm C: Chemotherapy · Log Rank · p = 0.0023 (Log-rank test stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (\<= 1 vs. \>= 2) as recorded in IRT) · Hazard ratio (hr): 0.65 · 95% CI 0.49 to 0.86Stratified Cox proportional hazard model
SecondaryOverall Survival (OS) in All Randomized Participants

Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the subject was known to be alive.

Time frame:
From the date of randomization to up to the date of death (up to approximately 88 months)
Reported as:
Median · Months
Overall Survival (OS) in All Randomized Participants
MonthsArm A: Nivolumab + IpilimumabArm B: Nivolumab + ChemotherapyArm C: Chemotherapy
Overall Survival (OS) in All Randomized Participants12.747 (11.269 to 15.474)13.207 (11.105 to 15.671)10.710 (9.396 to 12.090)
Statistical analysis
  • Arm A: Nivolumab + Ipilimumab vs Arm C: Chemotherapy · Hazard ratio (hr): 0.77 · 95% CI 0.65 to 0.92Stratified Cox proportional hazard model
  • Arm B: Nivolumab + Chemotherapy vs Arm C: Chemotherapy · Hazard ratio (hr): 0.77 · 95% CI 0.65 to 0.92Stratified Cox proportional hazard model
SecondaryProgression-free Survival (PFS) in All Randomized Participants as Assessed by BICR

Progression-free survival (PFS) is defined as the time from randomization to the date of the first documented progressive disease (PD) per Blinded Independent Central Review (BICR) or death due to any cause. Participants who die without a reported prior PD per BICR (and die without start of subsequent therapy) will be considered to have progressed on the date of death. Participants who did not have documented PD per BICR per RECIST1.1 criteria and who did not die, will be censored at the date of the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on-study tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date. Participants who started any subsequent anti-cancer therapy without a prior reported PD per BICR will be censored at the last tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.

Time frame:
From the date of randomization to up to the date of the first documented disease progression or death (up to approximately 88 months)
Reported as:
Median · Months
Progression-free Survival (PFS) in All Randomized Participants as Assessed by BICR
MonthsArm A: Nivolumab + IpilimumabArm B: Nivolumab + ChemotherapyArm C: Chemotherapy
Progression-free Survival (PFS) in All Randomized Participants as Assessed by BICR2.891 (2.661 to 4.172)5.782 (5.520 to 6.998)5.618 (4.304 to 5.914)
Statistical analysis
  • Arm A: Nivolumab + Ipilimumab vs Arm C: Chemotherapy · Hazard ratio (hr): 1.25 · 95% CI 1.04 to 1.50Stratified Cox proportional hazard model
  • Arm B: Nivolumab + Chemotherapy vs Arm C: Chemotherapy · Hazard ratio (hr): 0.82 · 95% CI 0.68 to 1.00Stratified Cox proportional hazard model
SecondaryObjective Response Rate (ORR) as Assessed by BICR

Objective response rate (ORR) is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). Best overall response (BOR) is defined as the best response designation as determined by BICR, recorded between the date of randomization and the date of objectively documented progression (per RECIST 1.1) or the date of subsequent anti-cancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions. Complete response is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.

Time frame:
From the date of randomization to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 88 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) as Assessed by BICR
Percentage of participantsArm A: Nivolumab + IpilimumabArm B: Nivolumab + ChemotherapyArm C: Chemotherapy
Participants with baseline PD-L1 status < 1%20.1 (14.3 to 27.1)41.7 (34.1 to 49.7)33.7 (26.6 to 41.5)
Participants with baseline PD-L1 status >= 1%35.4 (28.0 to 43.4)53.2 (45.1 to 61.1)19.9 (13.9 to 27.0)
Participants with baseline PD-L1 status < 5%22.3 (16.7 to 28.6)44.8 (37.8 to 51.9)30.9 (24.7 to 37.7)
Participants with baseline PD-L1 status >= 5%36.7 (28.1 to 45.9)51.7 (42.4 to 60.9)20.0 (13.1 to 28.5)
Participants with baseline PD-L1 status < 10%23.3 (17.9 to 29.5)46.1 (39.4 to 53.0)29.3 (23.5 to 35.8)
Participants with baseline PD-L1 status >= 10%36.9 (27.6 to 47.0)50.0 (39.9 to 60.1)21.6 (13.9 to 31.2)
Participants with baseline PD-L1 status indeterminate, not evaluable, or missing33.3 (0.8 to 90.6)—0.0 (0.0 to 84.2)
All randomized participants27.4 (22.6 to 32.6)47.4 (41.8 to 53.0)26.9 (22.1 to 32.0)

Adverse events

Collected over All cause mortality was collected till 88 months and Serious and Non-Serious AEs from first dose (Day 1) to 100 days post last dose (up to 43 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Nivolumab + Ipilimumab270/325 (83.1%)243/322 (75.5%)301/322 (93.5%)
Arm B: Nivolumab + Chemotherapy273/321 (85%)226/310 (72.9%)307/310 (99%)
Arm C: Chemotherapy286/324 (88.3%)174/304 (57.2%)288/304 (94.7%)
Most frequent serious events
Showing 10 of 342
Most frequent serious events
EventArm A: Nivolumab + IpilimumabArm B: Nivolumab + ChemotherapyArm C: Chemotherapy
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)59/32261/31065/304
PneumoniaInfections and infestations32/32233/31020/304
DysphagiaGastrointestinal disorders12/32221/31016/304
PyrexiaGeneral disorders and administration site conditions14/3227/3107/304
Oesophageal stenosisGastrointestinal disorders3/3229/31013/304
PneumonitisRespiratory, thoracic and mediastinal disorders13/3226/3101/304
VomitingGastrointestinal disorders5/3224/31012/304
Pneumonia aspirationInfections and infestations12/3226/3108/304
Acute kidney injuryRenal and urinary disorders2/3229/3104/304
Hepatic function abnormalHepatobiliary disorders9/3220/3101/304
Most frequent other events
Showing 10 of 62
Most frequent other events
EventArm A: Nivolumab + IpilimumabArm B: Nivolumab + ChemotherapyArm C: Chemotherapy
NauseaGastrointestinal disorders88/322207/310172/304
Decreased appetiteMetabolism and nutrition disorders70/322161/310156/304
AnaemiaBlood and lymphatic system disorders84/322156/310108/304
ConstipationGastrointestinal disorders87/322142/310138/304
StomatitisGastrointestinal disorders34/322100/31075/304
DiarrhoeaGastrointestinal disorders84/32298/31063/304
FatigueGeneral disorders and administration site conditions56/32283/31063/304
VomitingGastrointestinal disorders53/32277/31060/304
Neutrophil count decreasedInvestigations12/32275/31061/304
PyrexiaGeneral disorders and administration site conditions76/32265/31048/304

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: Nivolumab + IpilimumabArm B: Nivolumab + ChemotherapyArm C: ChemotherapyTotal
Mean62.2 ± 9.163.1 ± 9.263.3 ± 8.762.9 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Nivolumab + IpilimumabArm B: Nivolumab + ChemotherapyArm C: ChemotherapyTotal
Female566849173
Male269253275797
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Nivolumab + IpilimumabArm B: Nivolumab + ChemotherapyArm C: ChemotherapyTotal
White798584248
Black or African American41611
American Indian or Alaska Native1214
Asian Indian1438
Chinese717470215
Japanese131126137394
Asian Other28231768
Other106622
08

Study locations

190 sites
  • Local Institution - 0191
    Mobile, Alabama 36608, United States
  • Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Usc/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Local Institution - 0188
    Denver, Colorado 80218, United States
  • University Of Miami Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Local Institution - 0186
    Miami, Florida 33176, United States
  • Local Institution - 0225
    Tampa, Florida 33612, United States
  • Local Institution - 0074
    Atlanta, Georgia 30322, United States
  • Local Institution - 0032
    Marietta, Georgia 30060, United States
  • Hackensack Meridian Jersey Shore University Medical Center
    Neptune City, New Jersey 07753, United States
  • Oncology Associates Of Oregon, Pc
    Eugene, Oregon 97401, United States
  • Northwest Cancer Specialists, P.C.
    Portland, Oregon 97227, United States
  • Local Institution - 0210
    Dallas, Texas 75246, United States
  • Local Institution - 0028
    Houston, Texas 77030, United States
  • Local Institution - 0190
    Roanoke, Virginia 24014, United States
  • Local Institution - 0203
    Morgantown, West Virginia 26506-9162, United States
  • Local Institution - 0048
    Buenos Aires, Buenos Aires 1417, Argentina
  • Local Institution - 0050
    Capital Federal, Buenos Aires 1264, Argentina
  • Local Institution - 0087
    La Rioja, La Rioja Province 5300, Argentina
  • Local Institution - 0086
    Rosario, Santa Fe Province 2000, Argentina
  • Local Institution - 0232
    Tamworth, New South Wales 2340, Australia
  • Local Institution - 0011
    Douglas, Queensland 4814, Australia
  • Local Institution - 0010
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0241
    Salzburg, 5020, Austria
  • Local Institution - 0017
    Salvador, Estado de Bahia 41950-640, Brazil
  • Local Institution - 0227
    Ipatinga, Minas Gerais 35160-158, Brazil
  • Local Institution - 0228
    Rio de Janeiro, Rio de Janeiro 22793-080, Brazil
  • Local Institution - 0021
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Local Institution - 0016
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Local Institution - 0019
    Barretos, São Paulo 14780-070, Brazil
  • Local Institution - 0226
    Jaú, São Paulo 17210-080, Brazil
  • Local Institution - 0018
    São José do Rio Preto, São Paulo 15090000, Brazil
  • Local Institution - 0020
    São Paulo, São Paulo 01246-000, Brazil
  • Local Institution - 0095
    Moncton, New Brunswick E1C 6Z8, Canada
  • Local Institution - 0082
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 0222
    Montreal, Quebec H4A 3J1, Canada
  • Local Institution - 0037
    Trois-Rivières, Quebec G8Z 3R9, Canada
  • Local Institution - 0053
    Santiago, Santiago Metropolitan 8320000, Chile
  • Local Institution - 0214
    Santiago, Santiago Metropolitan, Chile
  • Local Institution - 0207
    Hefei, Anhui 230022, China
  • Local Institution - 0197
    Hefei, Anhui 230061, China
  • Local Institution - 0182
    Beijing, Beijing Municipality 100032, China
  • Local Institution - 0179
    Beijing, Beijing Municipality 100071, China
  • Local Institution - 0216
    Beijing, Beijing Municipality 100853, China
  • Local Institution - 0217
    Fuzhou, Fujian 350014, China
  • Local Institution - 0219
    Fuzhou, Fujian 350025, China
  • Local Institution - 0199
    Shantou, Guangdong 515041, China
  • Local Institution - 0185
    Harbin, Heilongjiang 155040, China
  • Local Institution - 0193
    Zhengzhou, Henan 0, China
  • Local Institution - 0195
    Zhengzhou, Henan 450008, China
  • Local Institution - 0194
    Zhengzhou, Henan 450052, China
  • Local Institution - 0249
    Changsha, Hunan 410000, China
  • Local Institution - 0212
    Changsha, Hunan 410008, China
  • Local Institution - 0201
    Nanjing, Jiangsu 210000, China
  • Local Institution - 0180
    Changchun, Jilin 130021, China
  • Local Institution - 0183
    Xi'an, Shan3xi 710038, China
  • Local Institution - 0215
    Shanghai, Shanghai Municipality 200030, China
  • Local Institution - 0200
    Shanghai, Shanghai Municipality 200032, China
  • Local Institution - 0184
    Hangzhou, Zhejiang 310003, China
  • Local Institution - 0247
    Linhai, Zhejiang 317000, China
  • Local Institution - 0220
    Shenyang, 110042, China
  • Local Institution - 0248
    Xi'an, 0, China
  • Local Institution - 0059
    Bogotá, Bogota D.C. 0, Colombia
  • Local Institution - 0058
    Medellín, 050034, Colombia
  • Local Institution - 0224
    Montería, 230001, Colombia
  • Local Institution - 0094
    Pereira, 660004, Colombia
  • Local Institution - 0083
    Brno, 625 00, Czechia
  • Local Institution - 0008
    Brno, 656 53, Czechia
  • Local Institution - 0006
    Nový Jičín, 741 01, Czechia
  • Local Institution - 0099
    Odense, 5000, Denmark
  • Local Institution - 0116
    Lille, Nord 59000, France
  • Local Institution - 0114
    Caen, 14076, France
  • Local Institution - 0112
    Montpellier, 34090, France
  • Local Institution - 0113
    Rennes, 35042, France
  • Local Institution - 0242
    Toulouse, 31059, France
  • Local Institution - 0115
    Villejuif, 94800, France
  • Local Institution - 0035
    Hong Kong, 0, Hong Kong
  • Local Institution - 0070
    Kowloon, Hong Kong
  • Local Institution - 0085
    Bergamo, 24127, Italy
  • Local Institution - 0039
    Milan, 20133, Italy
  • Local Institution - 0084
    Padova, Padova, Italy
  • Local Institution - 0240
    Pisa, 56126, Italy
  • Local Institution - 0152
    Akita, Akita 010-8543, Japan
  • Local Institution - 0104
    Hirosaki-shi, Aomori 0368563, Japan
  • Local Institution - 0101
    Chiba, Chiba 260-8717, Japan
  • Local Institution - 0153
    Chiba, Chiba 2608670, Japan
  • Local Institution - 0173
    Kashiwa-shi, Chiba 2778577, Japan
  • Local Institution - 0169
    Matsuyama, Ehime 7900024, Japan
  • Local Institution - 0119
    Matsuyama, Ehime 7910280, Japan
  • Local Institution - 0174
    Fukuoka, Fukuoka 8111395, Japan
  • Local Institution - 0142
    Fukuoka, Fukuoka 8128582, Japan
  • Local Institution - 0103
    Fukushima, Fukushima 9601295, Japan
  • Local Institution - 0154
    Gifu, Gifu 5011194, Japan
  • Local Institution - 0176
    Ōta, Gunma 3738550, Japan
  • Local Institution - 0100
    Hiroshima, Hiroshima 7348551, Japan
  • Local Institution - 0111
    Sapporo, Hokkaido 060-8648, Japan
  • Local Institution - 0170
    Akashi-shi, Hyōgo 6738558, Japan
  • Local Institution - 0172
    Kobe, Hyōgo 6500017, Japan
  • Local Institution - 0118
    Kobe, Hyōgo 6500047, Japan
  • Local Institution - 0171
    Kanazawa, Ishikawa-ken 920-8530, Japan

Showing the first 100 of 190 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Zhang Y, Li C, Du K, Pengkhun N, Huang Z, Gong M, Li Y, Liu X, Li L, Wang D, Wang C, Chen F, Li J. Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis. Immunotherapy. 2023 Jul;15(10):737-750. doi: 10.2217/imt-2022-0236. Epub 2023 May 4. PubMed 37139963 ↗
  • Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50). Esophagus. 2023 Apr;20(2):291-301. doi: 10.1007/s10388-022-00970-1. Epub 2022 Nov 19. PubMed 36401133 ↗
  • Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380. PubMed 35108470 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Jan 2021, 42 months.

Results were first posted in Mar 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2017
First posted
May 8, 2017
StartActual
Jun 29, 2017
Primary completionActual
Jan 18, 2021
CompletionActual
Jan 13, 2025
Results first posted
Mar 2, 2022
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03143153
Responsible party
Sponsor
First posted
May 8, 2017
Start date
Jun 29, 2017
Primary completion
Jan 18, 2021
Completion
Jan 13, 2025
Results posted
Mar 2, 2022
Last update
Feb 17, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab · Cisplatin · Fluorouracil

Start the discussion